# A Study Investigating the Safety, Tolerability, and Efficacy of Elamipretide Topical Ophthalmic Solution for the Treatment of Fuchs' Corneal Endothelial Dystrophy (FCED)

> **NCT02653391** · PHASE1,PHASE2 · COMPLETED · sponsor: **Stealth BioTherapeutics Inc.** · enrollment: 22 (actual)

## Conditions studied

- Fuchs' Corneal Endothelial Dystrophy (FCED)

## Interventions

- **DRUG:** Part A Elamipretide 1.0% Ophthalmic Solution
- **DRUG:** Part B Elamipretide 3.0% Ophthalmic Solution
- **DRUG:** Part A Placebo
- **DRUG:** Part B Placebo

## Key facts

- **NCT ID:** NCT02653391
- **Lead sponsor:** Stealth BioTherapeutics Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-02
- **Primary completion:** 2018-03
- **Final completion:** 2018-12
- **Target enrollment:** 22 (ACTUAL)
- **Last updated:** 2021-09-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02653391

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02653391, "A Study Investigating the Safety, Tolerability, and Efficacy of Elamipretide Topical Ophthalmic Solution for the Treatment of Fuchs' Corneal Endothelial Dystrophy (FCED)". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT02653391. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*